VA
PCVX icon

Vident Advisory’s Vaxcyte PCVX Stock Holding History

Vident Advisory’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486K Sell
8,361
-1,143
-12% -$62.1K ﹤0.01% 1382
2026
Q1 		$552K Buy
9,504
+683
+8% +$37.1K ﹤0.01% 1200
2025
Q4 		$407K Buy
8,821
+1,007
+13% +$45K ﹤0.01% 1262
2025
Q3 		$281K Sell
7,814
-2,230
-22% -$73.9K ﹤0.01% 1427
2025
Q2 		$327K Buy
+10,044
New +$329K ﹤0.01% 1266
2024
Q4 		– Sell
-2,172
Closed -$248K – 1524
2024
Q3 		$248K Buy
+2,172
New +$196K 0.01% 1202

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vident Advisory's PCVX Position: Q2 2026 in Review

Vident Advisory reduced its Vaxcyte (PCVX) stake by 12% in Q2 2026, selling an estimated $62.1K and leaving 8,361 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #1382.

Vident Advisory first reported a position in PCVX in Q3 2024 and has held it in 6 quarters since. The position peaked at $552K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Vident Advisory held 8,361 shares of Vaxcyte worth $486K as of Q2 2026.
  • Vident Advisory sold 1,143 Vaxcyte shares in Q2 2026, an estimated $62.1K.
  • Vaxcyte made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1382 holding.
  • Vident Advisory first reported a position in Vaxcyte in Q3 2024 and has held it in 6 quarters since.
  • Vident Advisory's Vaxcyte position peaked at $552K in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.